InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.16
(
0.47%
)
US TECH 100
18,024.00
(
0.56%
)
Dow Jones
39,497.54
(
0.13%
)
Brent Oil
79.49
(
0.00%
)
Bitcoin
60,946.27
(
0.11%
)

Replies to post #1667 on Galectin Therapeutics Inc. (GALT)

Replies to #1667 on Galectin Therapeutics Inc. (GALT)
icon url

BelizeBeachTrader

11/10/14 4:05 PM

#1668 RE: thefamilyman #1667

Look at last page, biopsies listed as Secondary end point.

http://files.shareholder.com/downloads/AMDA-235HJQ/2903159175x0x793096/b9052389-3853-46eb-9e07-f6e293878b23/AASLDPresentation110914.pdf
icon url

BelizeBeachTrader

11/10/14 4:09 PM

#1669 RE: thefamilyman #1667

Also here:




http://investor.galectintherapeutics.com/releasedetail.cfm?ReleaseID=881702

Quote:

"Based on the robust pre-clinical efficacy and positive safety, tolerability and pharmacokinetics in the Phase 1 clinical trial and a pharmacodynamic effect, the Company is in a position to design a strong Phase 2 clinical trial to assess potential surrogate endpoints that are closely associated with clinical-related outcomes in patients with cirrhosis, including hepatic venous pressure gradient (HVPG) and morphometric analysis of collagen on liver biopsies," continued Dr. Traber. "To this end, the Company recently met with the"